CAS Number100986-85-4
SynonymsLevofloxacin; L-Ofloxacin; S-(-)-Ofloxacin; MFCD03265511; Levaquin; levoflaxacin; Tavanic
Molecular FormulaC18H20FN3O4
Molecular Weight361.37
Purity98.0-102.0 anhydrous basis (HPLC)%
Density1.5±0.1 g/cm3
Boiling Point571.5±50.0 °C at 760 mmHg
Melting Point218ºC
Appearancepowder or crystals
Symbol
Signal WordWarning
Please Login or Create an Account to: See VlP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 100986-85-4 |
| Catalog No. | 2A-9011173 |
| Chinese Name | 左氧氟沙星 |
| Synonyms | Levofloxacin; L-Ofloxacin; S-(-)-Ofloxacin; MFCD03265511; Levaquin; levoflaxacin; Tavanic |
| Molecular Formula | C18H20FN3O4 |
| Molecular Weight | 361.37 |
| Purity | 98.0-102.0 anhydrous basis (HPLC) |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 571.5±50.0 °C at 760 mmHg |
| Melting Point | 218ºC |
| Appearance | powder or crystals |
| Storage Condition | Sealed and stored in a cool, dry warehouse. |
| Application | Levofloxacin is a synthetic fluoroquinolone antibiotic that inhibits the supercoiling activity of bacterial DNA gyrase and prevents DNA replication. |
| HTC | 2934999090 |
| PubChem ID | 57648297 |
| MDL Number | MFCD00865049 |
| SMILES | OC(C(C1=O)=CN2C(C1=CC(F)=C3N4CCN(C)CC4)=C3OC[C@@H]2C)=O |
| InChI | 1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1 |
| InChI Key | GSDSWSVVBLHKDQ-JTQLQIEISA-N |
| Beilstein/REAXYS | 7327015 |
| NACRES Code | NA.85 |
| UNSPSC | 51102829 |
| Hazard Symbols | Transport |
| MSDS | msds/11173_1_100986_85_4.pdf |
| Bioactivity | Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3]. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86. [2]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014. [3]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014. Chemical & Physical Properties Density 1.5±0.1 g/cm3 Boiling Point 571.5±50.0 °C at 760 mmHg Melting Point 218ºC Molecular Formula C18H20FN3O4 Molecular Weight 361.367 Flash Point 299.4±30.1 °C Exact Mass 361.143799 PSA 75.01000 LogP 0.84 Vapour Pressure 0.0±1.7 mmHg at 25°C Index of Refraction 1.670 InChIKey GSDSWSVVBLHKDQ-JTQLQIEISA-N SMILES CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23 Storage condition Store at 0-5°C |
| Use of | Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3]. Properties Articles443 Name levofloxacin Synonym More Synonyms Levofloxacin Biological Activity Description Levofloxacin, a synthetic fluoroquinolone, is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3]. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86. [2]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014. [3]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014. Chemical & Physical Properties Molecular Formula C18H20FN3O4 Exact Mass 361.143799 PSA 75.01000 Index of Refraction 1.670 InChIKey GSDSWSVVBLHKDQ-JTQLQIEISA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Lamotrigine | 84057-84-1 | 2A-9011119 |
| Lansoprazole | 103577-45-3 | 2A-9011124 |
| Lansoprazole Sulphide compound | 103577-40-8 | 2A-9011125 |
| Letrozole | 112809-51-5 | 2A-9011156 |
| Levodopa | 59-92-7 | 2A-9011171 |
| levofloxacin Mesylate | 226578-51-4 | 2A-9011174 |
| Lincomycin hydrochloride | 7179-49-9 | 2A-9011191 |
| Linezolid | 165800-03-3 | 2A-9011192 |
| Lisinopril | 83915-83-7 | 2A-9011203 |
| Lopinavir | 192725-17-0 | 2A-9011228 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS